9AT: PHARMAKON ADVISORS, LP

other names

PHARMAKON ADVISORS, LP
BIOPHARMA PARTNERS LLC
PHARMAKON INVESTOR LLC

Adviser Profile

As of Date	03/31/2026
ADV Location	NEW YORK, NY, United States
Adviser Type - Large advisory firm
Number of Employees	15 25%
of those in investment advisory functions	9 29%
Registration	SEC, Approved, 03/30/2012

AUM^*	3,038,360,099 -3%
of that, discretionary	3,038,360,099 -3%
Private Fund GAV^*	1,870,085,438 10%
Avg Account Size	607,672,020 -3%
SMA’s	Yes
Private Funds	4
Contact Info	212 xxxxxxx
Websites

Client Types

- Pooled investment vehicles
- Other

Advisory Activities

- Portfolio management for pooled investment vehicles

Compensation Arrangments

- A percentage of assets under your management
- Performance-based fees

Fund Type	Count	GAV
Fund TypePrivate Equity Fund	Count4	GAV$1,870,085,438

Adviser	Hedge Fund	Liquidity Fund	Private Equity Fund	Real Estate Fund	Securitized Asset Fund	Venture Capital Fund	Other Fund	Total Private Fund GAV	AUM	#Funds
Adviser ARGONAUT PRIVATE CAPITAL, LP	Hedge Fund-	Liquidity Fund-	Private Equity Fund2.2b	Real Estate Fund-	Securitized Asset Fund-	Venture Capital Fund-	Other Fund-	Total Private Fund GAV2.2b	AUM3.0b	#Funds13
Adviser FIRST SENTIER INVESTORS	Hedge Fund8.7b	Liquidity Fund-	Private Equity Fund-	Real Estate Fund-	Securitized Asset Fund-	Venture Capital Fund-	Other Fund-	Total Private Fund GAV8.7b	AUM3.6b	#Funds5
Adviser HARBOR GROUP INTERNATIONAL, LLC	Hedge Fund-	Liquidity Fund-	Private Equity Fund2.8b	Real Estate Fund-	Securitized Asset Fund-	Venture Capital Fund-	Other Fund2.0b	Total Private Fund GAV4.8b	AUM3.8b	#Funds94
Adviser COVE HILL PARTNERS, L.P.	Hedge Fund-	Liquidity Fund-	Private Equity Fund5.4b	Real Estate Fund-	Securitized Asset Fund-	Venture Capital Fund-	Other Fund-	Total Private Fund GAV5.4b	AUM5.4b	#Funds11
Adviser TIGER INFRASTRUCTURE PARTNERS LP	Hedge Fund-	Liquidity Fund-	Private Equity Fund3.9b	Real Estate Fund-	Securitized Asset Fund-	Venture Capital Fund-	Other Fund-	Total Private Fund GAV3.9b	AUM3.9b	#Funds30
Adviser MIDDLEGROUND CAPITAL	Hedge Fund-	Liquidity Fund-	Private Equity Fund3.6b	Real Estate Fund-	Securitized Asset Fund-	Venture Capital Fund-	Other Fund-	Total Private Fund GAV3.6b	AUM4.0b	#Funds26
Adviser SHORE CAPITAL PARTNERS	Hedge Fund-	Liquidity Fund-	Private Equity Fund9.8b	Real Estate Fund-	Securitized Asset Fund-	Venture Capital Fund-	Other Fund125.0m	Total Private Fund GAV10.0b	AUM9.3b	#Funds67
Adviser TCG CAPITAL MANAGEMENT	Hedge Fund-	Liquidity Fund-	Private Equity Fund2.8b	Real Estate Fund-	Securitized Asset Fund-	Venture Capital Fund-	Other Fund-	Total Private Fund GAV2.8b	AUM2.6b	#Funds14
Adviser GIGAFUND	Hedge Fund-	Liquidity Fund-	Private Equity Fund11.6b	Real Estate Fund-	Securitized Asset Fund-	Venture Capital Fund3.1b	Other Fund-	Total Private Fund GAV17.8b	AUM15.0b	#Funds22
Adviser BAYPINE HOLDINGS LP	Hedge Fund-	Liquidity Fund-	Private Equity Fund5.1b	Real Estate Fund-	Securitized Asset Fund-	Venture Capital Fund-	Other Fund-	Total Private Fund GAV5.1b	AUM5.1b	#Funds13

Brochure Summary

Overview

A. Pharmakon Advisors, LP (also referred to as “we”, the “Firm” and “Pharmakon”), founded in 2009, is an investment services firm specializing in investment management for private funds that are deemed to be pooled investment vehicles and their respective feeder funds (collectively the “Funds”). Pharmakon also provides certain investment advisory services to a public limited company in the UK (the “UK Trust”). Throughout this Brochure, “clients”, when used respect to the Firm, refer to the Funds and the UK Trust. The principal owners of Pharmakon are Pedro Gonzalez de Cosio and Pablo Legorreta. B. Pharmakon specializes in offering investment management services to its clients, which are comprised of the Funds and the UK Trust. In providing our advisory services to our clients, we focus on acquiring high yielding debt securities and instruments, including senior secured debt and capped return royalties with short average lives, which are securitized

or collateralized by the assets and products of life sciences companies and the royalty payments on one or more life sciences products, as applicable, which we believe will have good sales visibility during the expected life of such securities or instruments. C. Our Firm tailors our advisory services to the individual needs and specified investment mandates of our clients; however, the Firm does not tailor advisory services to the underlying individual investors in the clients. We adhere to the investment strategy set forth in our clients’ confidential private placement memoranda, investment management agreements, prospectus and other governing documents as applicable. D. We do not participate in wrap fee programs. The amount of client assets that we manage, as of December 31, 2023 is approximately $3,128,821,083, all of which are managed on a discretionary basis. We manage the Funds and the UK Trust on a discretionary basis.

PHARMAKON ADVISORS, LP

Adviser Profile

Details

Client Types

Advisory Activities

Compensation Arrangments

Reported AUM

Private Funds

Employees

Private Funds Structure

Similar advisers

Brochure Summary

Overview